Acceleron Announces Closing of Initial Public Offering and Full-Exercise of
CAMBRIDGE, Mass. -- September 24, 2013
Acceleron Pharma, Inc. (NASDAQ:XLRN) today announced the closing of its
initial public offering of 6,417,000 shares of common stock, including 837,000
shares of common stock issued upon the exercise in full by the underwriters of
their option to purchase additional shares to cover over-allotments, at a
public offering price of $15.00 per share, before underwriting discounts.
Separately, in a concurrent, side-by-side private placement, Acceleron’s
collaboration partner, Celgene Corporation (NASDAQ:CELG), purchased 666,667
shares of common stock from Acceleron at the public offering price. Including
the private placement to Celgene, the aggregate net proceeds to the Company,
after underwriting discounts and commissions and other estimated offering
expenses, were approximately $96.7 million.
Citigroup and Leerink Swann acted as joint book-running managers for the
offering. Piper Jaffray & Co. acted as lead manager and JMP Securities LLC
acted as co-manager for the offering.
A registration statement relating to these securities was declared effective
on September 18, 2013. Copies of the final prospectus relating to the offering
may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY, 11717, or by email at email@example.com,
or by phone at 800-831-9146; or Leerink Swann, Attention: Syndicate
Department, One Federal Street, 37^th Floor, Boston, MA, 02110, or by email at
Syndicate@Leerink.com, or by phone at 800-808-7525.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of such state or jurisdiction.
Acceleron is a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of novel protein therapeutics for
cancer and rare diseases. The company is a leader in understanding the biology
of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large
and diverse group of molecules that are key regulators in the growth and
repair of tissues throughout the human body, and in targeting these pathways
to develop important new medicines. Acceleron has built a highly productive
R&D platform that has generated innovative clinical and preclinical protein
therapeutic candidates with novel mechanisms of action. These protein
therapeutic candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
Kevin F. McLaughlin, 617-649-9204
Senior Vice President and Chief Financial Officer
Suda Communications LLC
Maureen L. Suda, 585-387-9248
Press spacebar to pause and continue. Press esc to stop.